DURHAM, N.C.--(BUSINESS WIRE)--Jun. 14, 2018--
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma and other diseases of the eye, today announced that Richard
Rubino, Chief Financial Officer, will present in a fireside chat
discussion at the JMP Securities 2018 Life Science Conference onThursday, June 21, 2018 at 2:00pm Eastern Time in New York, NY. Mr.
Rubino will provide an Aerie overview and business update.
The fireside chat will be webcast live and may be accessed by visiting
Aerie's website at http://investors.aeriepharma.com/.
A replay of the webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the discovery,
development and commercialization of first-in-class therapies for the
treatment of patients with open-angle glaucoma and other diseases of the
eye. Aerie's first product, Rhopressa® (netarsudil ophthalmic
solution) 0.02%, for the reduction of elevated intraocular pressure
(IOP) in patients with open-angle glaucoma or ocular hypertension, was
approved by the U.S. Food and Drug Administration (FDA) in December 2017
and was launched in the U.S. market in April 2018. A link to the full
product label is available on the Aerie website at http://investors.aeriepharma.com.
Aerie’s advanced-stage product candidate, Roclatan™
(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a
fixed dose combination of Rhopressa® and widely-prescribed
PGA (prostaglandin analog) latanoprost, achieved its primary efficacy
endpoint in two Phase 3 registration trials, named Mercury 1 and Mercury
2, and also achieved successful 12-month safety and efficacy results in
Mercury 1. The Roclatan™ NDA submission took place in May 2018. Aerie is
also focused on global expansion and the development of additional
product candidates and technologies in ophthalmology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180614005028/en/
Source: Aerie Pharmaceuticals, Inc.
Tad Heitmann, 949-526-8747
McClellan, Inc., on behalf of Aerie Pharmaceuticals